Kevin

S-DISCO guest lectures during the first semester

S-DISCO guest lectures during the first semester

In the first semester, the S-DISCO students had the pleasure to follow several guest lectures during the courses. In the course ‘Pharmaceuticals in the Environment’, prof. Adrian Covaci (University of Antwerp) talked about the wastewater-based epidemiology of psychoactive compounds, thereby combining multiple disciplines for this study. For the course ‘Sustainable Landscape of Pharmaceutical Discovery’, 3 […]

COP15 UN Biodiversity Conference

COP15 UN Biodiversity Conference

The ubiquitous presence of pharmaceuticals in the environment contributes to biodiversity threats. Their presence and bioactivity in plants, invertebrates, (soil)microorganisms, fish and other vertebrates may influence the genetic, species and ecosystem diversity. Novel and global approaches are urgently needed to cope with the historical pollution and minimize future contaminations. UN Biodiversity Conference (COP 15), 7 […]

World Antimicrobial Awareness Week (WAAW)

World Antimicrobial Awareness Week (WAAW)

We need to apply a One Health approach to cope with antimicrobial resistance: all sectors must actively be involved in strengthening preventive measures. This includes development and access to safe vaccines, rational use of antimicrobials, sound antimicrobials waste management and discovery of novel targets to develop safer medicines. World Antimicrobial Awareness Week (WAAW) is celebrated […]

S-DISCO represented at EPSA student congress

S-DISCO represented at EPSA student congress

During the 18th EPSA Autumn Assembly in Athens, we had the opportunity to present the S-DISCO program to the European Pharmaceutical students attending the congress. During an interactive session on sustainability in drug discovery, DruQuaR scientist Kevin Van der borght discussed with the students how to implement sustainability in the earliest phases of the drug […]

FDA guidance on Competitive Generic Therapies (CGT)

FDA guidance on Competitive Generic Therapies (CGT)

As a consequence of the FDA Reauthorization Act of 2017, a draft guidance about competitive generic therapy (CGT) is published with the aim to incentivize generic competition in USA. The designation of medicine as CGT, the request for designation, the expedited review and the 180 days exclusivity period are explained in this draft guideline (rev.1). […]

EMA/HMA statement on interchangeability of biosimilars

EMA/HMA statement on interchangeability of biosimilars

EMA and the Heads of Medicines Agencies (HMA) have recently issued a joint statement confirming that biosimilar medicines approved in the European Union (EU) are interchangeable with their reference medicine or with an equivalent biosimilar. Interchangeability of biosimilars without additional clinical trials required will improve the global accessibility of biological medicines.

AskMeAnything session by Young MedChem Forum on September 22, 2022

AskMeAnything session by Young MedChem Forum on September 22, 2022

The Young MedChem Forum (YMCF) of the Société de Chimie Thérapeutique (SCT) is organizing its second AskMeAnything session on September 22 from 6 p.m. to 7:30 p.m. for doctoral and post-doctoral students in medicinal and organic chemistry. Registration before September 20 https://forms.gle/yTM8nWExNxwPiPqe7 Follow the YMCF on LinkedIn and Twitter.

Scroll to Top